BPC-157 side effects: what the studies found
Real adverse event rates, clinical trial discontinuation numbers, and documented safety warnings from peer-reviewed literature.
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Safety summary: BPC-157
- Evidence level Animal studies only
- FDA approvedNo
- Trial discontinuationNo completed randomized controlled trials in humans exist to determine clinical discontinuation rates.
- WADA sport statusProhibited
In short: No serious adverse events have been reported in the few human reports, but those reports cover under 20 people in total and cannot rule out risk. Reviewers note there are no real clinical safety data in humans. Real-world risk also comes from unregulated manufacturing: contamination, wrong dose, and wrong compound. Because BPC-157 promotes blood vessel growth in lab models, some researchers have raised a theoretical concern in people with cancer; this is unproven either way.
Not approved by the FDA or Health Canada. Prohibited at all times in sport by WADA under Category S0.
Most common side effects
Reported symptoms in clinical trials and published pharmacology literature:
| Symptom | Reported rate | Clinical context & notes |
|---|---|---|
| No controlled human frequency data | Unknown | Almost all published studies are in rats or mice. Human clinical safety trials have not been conducted. |
| Injection site pain / bruising | Anecdotal | Reported in online user communities from unsterile subcutaneous injection. |
| Headache & nausea | Anecdotal | Occasionally reported by users online, but unverified in controlled clinical trials. |
Serious risks and warnings
Potential adverse reactions and biological risks identified in research:
- Contamination and infection risk: Gray-market peptides sold "for research use only" are produced without pharmaceutical GMP inspections, risking endotoxin exposure or septic abscesses.
- Theoretical angiogenic risk in cancer: Because BPC-157 stimulates VEGF and new blood vessel formation in preclinical models, researchers have raised theoretical concerns about accelerating occult tumor growth.
- Unknown long-term organ toxicity: There are no Phase 2 or Phase 3 human toxicological studies to confirm safety for heart, kidney, or endocrine function.
Contraindications
This compound should not be used in individuals with:
- Active cancer or malignancy (theoretical angiogenesis concern)
- Competitive athletes under WADA drug testing
- Use of non-sterile gray-market products
Common questions about BPC-157 safety
Has BPC-157 been proven safe in humans?
No. A 2025 systematic review confirmed there are no clinical safety data in humans. The entire published human safety literature consists of an uncontrolled retrospective review of 17 knee patients and a 2-person IV pilot study.
Why is buying BPC-157 online dangerous?
Health Canada and regulatory chemists note that "research chemical" products bought online frequently contain incorrect doses, synthesis byproducts, lack sterility, and may not contain the advertised compound at all.
Can BPC-157 cause tumors to grow?
BPC-157 has been shown in rodent and cell studies to promote angiogenesis (formation of new blood vessels). While this helps heal injured tissue in lab animals, tumors require blood vessel recruitment to grow, creating a theoretical risk that has never been studied in humans.